Boston-based Joslin Diabetes Center has named Peter Amenta, MD, PhD, president and CEO, according to a Boston Business Journal report.
Here are five things to know Dr. Amenta.
1. His appointment is effective Oct. 5.
2. He currently serves as professor of pathology and laboratory medicine at New Brunswick, N.J.-based Rutgers Robert Wood Johnson Medical School.
3. Previously, he served as dean of the Rutgers Robert Wood Johnson Medical School for eight years and sat on the Joslin board of trustees for five years.
4. Of his new role, Dr. Amenta said, "Our vision for Joslin's future is strong; we all want to cure diabetes and as Joslin's leadership we need to make sure we have the financial capability and systems in place to go forward to accomplish this. We will be a highly effective and efficient organization, well positioned to continue making advancements in research and clinical care," according to the report.
5. Dr. Amenta's appointment comes about a week after John L. Brooks III resigned as president, CEO and member of the board of trustees at Joslin.
More articles on healthcare executive moves:
Arkansas interim CEO resigns over physician controversy: 4 things to know
SLU working toward succession plan for medical school dean, names Dr. Robert Heaney CEO of physician group